CervoMed Presents New Insights Into Neflamapimod's Treatment Effects In Dementia with Lewy Bodies At The Alzheimer's Association International Conference 2026

CervoMed Inc.

CervoMed Inc.

CRVO

0.00

New analyses of Phase 2b clinical trial reinforce treatment effect of neflamapimod observed relative to placebo in "pure" DLB and support selection of 50 mg TID for planned Phase 3 study in DLB

Neflamapimod produced durable slowing of basal forebrain atrophy and increased basal forebrain connectivity relative to placebo in trial, reinforcing the basal forebrain as a key therapeutic target in DLB

New Phase 2 study showed an 80 mg twice-daily dose of neflamapimod met its primary safety, tolerability, and pharmacokinetic objectives, with encouraging secondary findings on clinical activity

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.